Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALVARO M MURCIA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1104822261
CMS profile
231014
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$127.06

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $107.75 3
Education $19.31 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Edwards Lifesciences Corporation $89.62 2
Novartis Pharmaceuticals Corporation $19.31 1
Abbott Laboratories $18.13 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALVARO M MURCIA

NPI 1104822261 · CMS profile ID 231014

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104822261?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104822261?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104822261?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1104822261?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $127.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Edwards Lifesciences Corporation $63.7405/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225203017 CMS
Abbott Laboratories $18.1305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240783027 CMS
Edwards Lifesciences Corporation $25.8803/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225203011 CMS
Novartis Pharmaceuticals Corporation $19.3103/25/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1200601661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $606.94 32
PY2020 $366.85 18
PY2021 $465.58 22
PY2023 $20.75 1
PY2024 $169.48 4
PY2025 $127.06 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $406,482.03 21
PY2024 Principal investigator $1,460,913.18 46
PY2023 Principal investigator $709,095.23 72
PY2022 Principal investigator $649,259.15 51
PY2021 Principal investigator $536,745.12 32
PY2020 Principal investigator $88,190.48 30
PY2019 Principal investigator $148,033.20 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $126.30 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228728089
Principal investigator 1 PFIZER INC. $110.64 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228728311
Principal investigator 1 PFIZER INC. $126.30 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228728537
Principal investigator 1 PFIZER INC. $98.48 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228728539
Principal investigator 1 PFIZER INC. $110.64 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228729017
Principal investigator 1 PFIZER INC. $98.48 12/26/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228729119
Principal investigator 1 PFIZER INC. $2,574.00 12/17/2025 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729124
Principal investigator 1 AstraZeneca Pharmaceuticals LP $72,622.50 09/03/2025 Non-covered Recipient Entity
DOING BETTER CLINICAL RESEARCH USA, CORP
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185547621
Principal investigator 1 PFIZER INC. $16,553.16 08/28/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228767139
Principal investigator 1 PFIZER INC. $12,733.20 07/25/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228782945
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,789.22 06/12/2025 Non-covered Recipient Entity
DBC RESEARCH USA
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190310923
Principal investigator 1 PFIZER INC. $2,100.00 05/06/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228773849
Principal investigator 1 PFIZER INC. $9,165.96 03/28/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228781805
Principal investigator 1 PFIZER INC. $20,047.50 03/18/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228787984
Principal investigator 1 PFIZER INC. $12,028.50 03/12/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228794939
Principal investigator 1 PFIZER INC. $7,425.00 03/04/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228722570
Principal investigator 1 PFIZER INC. $44,550.00 02/26/2025 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1228752515
Principal investigator 1 PFIZER INC. $12,000.00 02/06/2025 Non-covered Recipient Entity
DBC Research USA Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228759610
Principal investigator 1 Novartis Pharmaceuticals Corporation $142,632.86 01/27/2025 Non-covered Recipient Entity
DBC RESEARCH USA
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310919
Principal investigator 1 PFIZER INC. $374.00 01/14/2025 Non-covered Recipient Entity
DBC RESEARCH USA LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1228733164
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,215.29 01/07/2025 Non-covered Recipient Entity
DBC RESEARCH USA
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310921